Morgan Stanley initiated coverage of Novartis with an Equal Weight rating and $114 price target. The analyst added six American depository receipts to the firm’s European Union Pharmaceuticals coverage. The stock’s fundamental views are fully aligned with those the firm has on the underlying stocks, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NVS:
- OPDP says Novartis’ Kisqali TV ad makes false or misleading representations
- Novartis says Lutathera reduced risk of disease progression, death in study
- Novartis price target raised to $123 from $119 at Jefferies
- Novartis price target raised to CHF 97 from CHF 92 at Morgan Stanley
- Novartis upgraded to Buy from Neutral at UBS
